She missed her second dose because she was sick; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team for a Pfizer sponsored program (159558). The reporter is the patient.  A 54 year-old female patient received bnt162b2 (BNT162B2), administered in arm, administration date 02Apr2021 13:30 (Lot number: ER8734, Expiration Date: Jul2021) at the age of 54 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "COVID-19", start date: Nov2020 (unspecified if ongoing); "Thyroid" (ongoing). Concomitant medication(s) included: SYNTHROID taken for thyroid disorder. The following information was reported: ILLNESS (non-serious), described as "She missed her second dose because she was sick". Relevant laboratory tests and procedures are available in the appropriate section.  Additional information: The patient would like to know if it was recommended to get the second dose of the vaccine after she had the COVID 19 virus. She had the virus in Nov2020 before receiving the first dose of the vaccine in Apr2021. The patient stated that she had the first dose of the Pfizer COVID 19 vaccine on 02Apr2021. She did not have the second dose. She wanted to know if it was recommended for her to receive the second dose even though its been so long from her first dose. Relayed to patient that she did not need to start the series over but just received the second dose of the vaccine. The patient asked what were the 6 months topline analysis results of the Pfizer-BioNTech COVID-19 Vaccine. Response: On 01Apr2021, Pfizer and BioNTech announced an updated topline analysis up to 6 months following second dose of Landmark COVID-19 Vaccine Study. Analysis of 927 confirmed symptomatic cases of COVID-19 demonstrates Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) is effective with 91.3% vaccine efficacy observed against COVID-19, measured seven days through up to 6 months after the second dose. Vaccine was 100% effective in preventing severe disease as defined by the Centers for Disease Control and Prevention (CDC) and 95.3% effective in preventing severe disease as defined by the Food and Drug Administration (FDA). Vaccine was 100% effective in preventing COVID-19 cases in country, where the B.1.351 lineage is prevalent. Vaccine safety now evaluated in more than 44,000 participants 16 years of age and older, with more than 12,000 vaccinated participants having at least six months follow-up after their second dose. Pfizer and BioNTech plan to share these results with worldwide regulatory agencies soon. The press release is available at withheld: Please note that the "Pfizer-BioNTech COVID-19 Vaccine - Antibody Persistence and Duration of Immunity" SRD has been updated to include the Press Release information. The report was related to a study or programme. There were no investigation assessment. The patient had her first dose of Pfizer COVID-19 Vaccine 02Apr2021 and she missed her second dose because she was sick. The patient was scheduled for 23Apr2021. The patient did not receive any other vaccines within 4 weeks. The patient did not had laboratory test recently.  The lot/batch number is not available despite the follow-up attempts made. Follow-up attempts completed. No further information is expected.